Omeros Corporation discovers, develops, and commercializes small-molecule and protein therapeutics.The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and atypical hemolytic uremic syndrome (aHUS) The company was incorporated in 1994 and headquartered in Seattle, Washington.
